Physician profile
Ling Cui
NPI 1306392675
$560.71
in general payments reported to CMS, 2019-2025
16 companies · $260 in 2025
The $260 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $11.64 · 2021: $17.40 · 2022: $57.59 · 2023: $190 · 2024: $24.59 · 2025: $260.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $474.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $474.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Insulet Corporation | $105.80 | 2025 | Omnipod |
| Amryt Pharma Holdings Ltd | $85.68 | 2022-2023 | Myalept, Mycapssa |
| Recordati_rare_diseases_inc. | $64.62 | 2025 | Isturisa |
| Horizon Therapeutics Plc | $38.47 | 2023 | Tepezza |
| Ascensia Diabetes Care US INC. | $32.66 | 2023 | |
| Abbott Laboratories | $26.97 | 2023 | Freestyle Libre 2 |
| Sanofi-Aventis U.S. LLC | $26.52 | 2025 | |
| Chiesi USA, INC. | $24.59 | 2024 | Myalept |
| Corcept Therapeutics | $24.34 | 2025 | Korlym |
| Takeda Pharmaceuticals U.S.A., INC. | $23.90 | 2023 | Ninlaro |
| Alexion Pharmaceuticals, INC. | $23.27 | 2023 | Strensiq |
| Bayer Healthcare Pharmaceuticals INC. | $20.89 | 2025 | |
| Ascendis Pharma Endocrinology INC | $17.50 | 2025 | Yorvipath |
| Xeris Pharmaceuticals, INC. | $17.40 | 2021 | |
| Novo Nordisk INC | $16.46 | 2022 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $11.64 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ling Cui listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.